Wuhan Calmland Pharmaceuticals Co., Ltd. – FDA Inspection, Jul 12, 2019

Record Details

This FDA Inspection record concerns Wuhan Calmland Pharmaceuticals Co., Ltd., with an inspection on July 12, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.

Company: Wuhan Calmland Pharmaceuticals Co., Ltd.
Inspection Date: July 12, 2019
Product Type: Drugs
Office: Center for Drug Evaluation and Research
Person: Zhongren Wu (FDA Associated Person)

View Company Profile

ID · 5cf03923-58e3-46c9-ab6c-05bf781c0b79

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number: 1098764
FDA center: Human Drugs
Project area: Drug Quality Assurance
Outcome: Form 483 issued

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Wuhan Calmland Pharmaceuticals Co., Ltd.

FDA Inspection

Wuhan Calmland Pharmaceuticals Co., Ltd.July 12, 2019